Aptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last year

“2024 was a successful year for Aptevo, as we’ve demonstrated the power of our science and our commitment to advancing oncology care. From the remarkable progress of mipletamig in AML, where 100% of patients in Cohort 1 of the RAINIER study achieved remission within 30 days, to the positive Phase 1 outcomes for ALG.APV-527 in solid tumors, we are delivering on the promise of our bispecifics to transform patient outcomes. These achievements are not just milestones-they’re a testament to the ingenuity, dedication, and passion of our team. With every success, we are reinforcing Aptevo’s position as a leader in the development of bispecific anti-cancer agents,” said Marvin White, President and CEO of Aptevo. ” The bottom line is that armed with the data and momentum of 2024, Aptevo is well poised for growth in 2025.”